Gene study could unlock diabetes mystery
NCT ID NCT06972407
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how a common genetic change (the T allele at rs7903146) affects the pancreas's own production of GLP-1, a hormone that helps control blood sugar. Researchers will give 80 healthy adults a drug that blocks GLP-1 receptors to see how their insulin and glucagon levels change. The goal is to understand why this gene variant raises the risk of type 2 diabetes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Exendin 9-39 (a GLP-1 receptor blocker)
What this could lead to
If successful, this could clarify how a common gene variant raises diabetes risk, potentially pointing toward new prevention or treatment strategies.
What could go wrong
This is an early-phase, small study (80 people) focused on understanding biology, not testing a treatment. It may not lead to direct patient benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE2DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States